SCHEMBL3699216

SCHEMBL3699216

c1ccc2c(-c3ccc4c(c3)OCO4)nnc(Nc3ccc(Oc4ccnc5ccsc45)cc3)c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.48
POLB P06746 3/20 0.48
NPSR1 Q6W5P4 2/20 0.48
GAA P10253 1/20 0.45
HSD17B10 Q99714 4/20 0.43
ALOX15 P16050 2/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
TP53 P04637 4/20 0.42
ALDH1A1 P00352 3/20 0.42
USP2 O75604 3/20 0.42
KDM4E B2RXH2 3/20 0.42
TDP1 Q9NUW8 2/20 0.42
PPARG P37231 1/20 0.42
RECQL P46063 1/20 0.42
BLM P54132 1/20 0.42
NCOA2 Q15596 1/20 0.42
NCOA1 Q15788 1/20 0.42
PDE10A Q9Y233 1/20 0.42
MET P08581 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3707651 0.89 PDE10A (0.44) MAPTPOLBNPSR1TP53ALDH1A1
SCHEMBL3700780 0.87 POLB (0.42) MAPTPOLBGAATP53USP2
SCHEMBL3699715 0.86 POLB (0.52) MAPTPOLBNPSR1GAATP53
SCHEMBL3699432 0.85 MAPT (0.48) MAPTPOLBNPSR1GAAHSD17B10
SCHEMBL3707198 0.84 AURKA (0.51) MAPTPOLBNPSR1GAATP53
SCHEMBL2209159 0.84 KDR (0.50) MAPTPOLBGAAUSP2KDM4E
SCHEMBL2210655 0.82 MAPT (0.47) MAPTPOLBNPSR1GAAHSD17B10
SCHEMBL2978920 0.81 MAPT (0.47) MAPTPOLBNPSR1GAAHSD17B10
SCHEMBL3705713 0.78 AURKA (0.61) MAPTPOLBTP53ALDH1A1USP2
SCHEMBL15664102 0.77 MAPT (0.46) MAPTPOLBNPSR1TP53ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122847-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2012-05-17 US claimed
EP-2137177-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2014-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122847-A1 AURORA KINASE MODULATORS AND METHOD OF USE AURKC, AURKA, CDK1 MAPT 1693/4885POLB 1671/4885NPSR1 2810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.